Experts and drug regulators said they await subsequent trial results of Globe Biotech Ltd’s prospective COVID-19 vaccine as the company said the preliminary animal trial of their inoculate yielded encouraging outcome. “We await the subsequent trials, if they succeed, it will be a landmark event for Bangladesh,” Head of National Advisory Technical Committee on COVID-19 Professor Dr Mohammad Shahidullah told journalists.
He said the prospective vaccine could protect millions of Bangladeshis from the deadly virus but preferred to be cautious about the venture saying “it’s a huge task”. Shahidullah’s comments came as the company said they made important headway carrying out initial trial of the shot on five rabbits with encouraging results.
“We found that antibodies were developed in those rabbits and we are analyzing the blood samples and these anybodies will neutralize their antigens,” Globe Biotech spokesman Dr Asif Mahmud told journalists.
The company earlier this month claimed to have emerged as a potential COVID-19 vaccine maker amid races of multinational drug companies to develop inoculates against the virus.
